中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.032 seconds)

    Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds
    42.
    发明申请
    Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds 审中-公开
    六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物

    公开(公告)号：US20140323474A1

    公开(公告)日：2014-10-30

    申请号：US14325409

    申请日：2014-07-08

    Applicant: Pfizer Inc.

    Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Jennifer Elizabeth Davoren ,  Brian Thomas O'Neill

    IPC: C07D513/04

    CPC classification number: A61K31/542 ,  C07D513/04

    Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    Abstract translation: 本发明提供式I化合物及其互变异构体，以及化合物和互变异构体的药学上可接受的盐，其中化合物具有其中变量R1，R2，R3，R4和x如说明书中所定义的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

    Heteroaromatic compounds and their use as dopamine D1 ligands
    43.
    发明授权
    Heteroaromatic compounds and their use as dopamine D1 ligands 有权
    杂芳族化合物及其作为多巴胺D1配体的用途

    公开(公告)号：US08822494B2

    公开(公告)日：2014-09-02

    申请号：US14072563

    申请日：2013-11-05

    Applicant: Pfizer Inc.

    Inventor： Jennifer Elizabeth Davoren ,  Amy Beth Dounay ,  Ivan Viktorovich Efremov ,  David Lawrence Firman Gray ,  Scot Richard Mente ,  Steven Victor O'Neil ,  Bruce Nelsen Rogers ,  Chakrapani Subramanyam ,  Lei Zhang

    IPC: C07D401/04 ,  C07D401/14 ,  A61K31/437

    CPC classification number: C07D471/04 ,  A61K31/437 ,  C07D401/04 ,  C07D401/14 ,  C07D519/00

    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.

    Abstract translation: 本发明部分提供式I化合物及其药学上可接受的盐和上述的N-氧化物; 制备过程; 中间体用于制备; 和含有这些化合物，盐或N-氧化物的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如，其认知和负面症状），认知障碍（例如，认知障碍相关 精神分裂症，AD，PD或药物治疗），ADHD，冲动，强迫性赌博，暴饮暴食，孤独症谱系障碍，MCI，年龄相关认知衰退，痴呆，RLS，帕金森病，亨廷顿舞蹈病，焦虑，抑郁，MDD，TRD 和双相情感障碍。

Patent Agency Ranking